The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies

Abstract

The antigen defined by MAb 17–1A, raised against colorectal cancer cells and currently used in immuno‐therapy trials, is a 37 kDa protein containing N‐linked glycans as demonstrated by inhibition of glycosylation with tunicamycin. The 17–1A antigen (17–1A Ag) is broadly distributed in normal epithelial tissues and is also found in various types of carcinoma. Quantitative differences in expression between normal and malignant tissues were only apparent in gastric carcinomas. After immunizing mice with fresh colon carcinoma tissue, 4 MAbs were obtained that showed the same tissue reaction pattern as MAb 17–1A and recognized the 17–1A Ag as judged from precipitation and immunoblotting experiments. MAbs M72 and M74 reacted with an anti‐idiotypic serum directed against the original MAb 17–1A and were able to block 17–1A binding. In contrast, M77 and M79 are directed against a different epitope. This makes them potentially interesting for passive immunotherapy in regimens involving a combination of MAbs.